Sanofi (SNYNF) Share-based Compensation (2009 - 2021)
Sanofi (SNYNF) posted Share-based Compensation of $2.1 million for Q4 2021, down 99.96% sequentially from $5.2 billion in Q2 2021, and up 7.94% YoY from $1.9 million in Q4 2020.
Sanofi (SNYNF) Share-based Compensation (2009 - 2021) Analysis & Trends
Sanofi (SNYNF) has 7 years of Share-based Compensation data on file, last reported at $2.1 million in Q4 2021.
- Quarterly Share-based Compensation rose 7.94% year-over-year to $2.1 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $116.5 million (changed N/A YoY) and the FY2025 annual result came in at $364.3 million, up 22.65% from the prior year.
- Share-based Compensation eased to $2.1 million in Q4 2021 per SNYNF's latest filing, from $5.2 billion in the prior quarter.
- The five-year high for Share-based Compensation was $5.2 billion in Q2 2021, with the low at $1.5 million in Q4 2019.
- Average Share-based Compensation over 3 years is $1.3 billion, with a median of $2.0 million recorded in 2020.
- Year-over-year, Share-based Compensation rose 23.1% in 2020 and advanced 7.94% in 2021.
- Sanofi's Share-based Compensation stood at $1.5 million in 2019, then increased by 23.1% to $1.9 million in 2020, then climbed by 7.94% to $2.1 million in 2021.
- Business Quant data shows SNYNF's Share-based Compensation at $2.1 million in Q4 2021, $5.2 billion in Q2 2021, and $1.9 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 161.00 Mn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 300.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 444.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 185.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 75.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 218.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 272.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Sanofi | - | - | 9.49 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 2.06 Mn |
| Dec 31, 2021 | 2.06 Mn |
| Jun 30, 2021 | 5.17 Bn |
| Jun 30, 2021 | 5.17 Bn |
| Dec 31, 2020 | 1.91 Mn |
| Dec 31, 2020 | 1.91 Mn |
| Dec 31, 2019 | 1.55 Mn |
| Dec 31, 2019 | 1.55 Mn |
| Dec 31, 2015 | 3.08 Bn |
| Dec 31, 2015 | 3.08 Bn |
| Jun 30, 2013 | 110.99 Mn |
| Jun 30, 2013 | 110.99 Mn |
| Dec 31, 2012 | 2.80 Bn |
| Dec 31, 2012 | 2.80 Bn |
| Dec 31, 2009 | 2.50 Bn |
| Dec 31, 2009 | 2.50 Bn |